Abstract 459P
Background
With cancer as the leading cause of death in Korea and globally, addressing non-cancer mortality, specifically cardiovascular disease, is critical. Dyslipidemia, a significant risk factor for cardiovascular disease, requires proper management in cancer survivors. This study aims to analyze factors associated with undertreatment of dyslipidemia in cancer survivors and investigate the impact of the National Health Screening Program (NHSP) on undertreatment in Korea.
Methods
This cross-sectional study analyzed data from the Korea National Health and Nutrition Survey (KNHANES) conducted between 2007 and 2019. It included 2,226 participants (792 males, 1,434 females) aged 40-75 who had a history of cancer. Self-reported questionnaires collected information following the 2018 Cholesterol Treatment Guidelines by the American College of Cardiology/American Heart Association. Multiple logistic regression analysis with integrated weights was performed.
Results
Among cancer survivors, 16.3% received treatment for dyslipidemia. Of those who were untreated, 46.64% had normal blood lipid levels, while 37.0% were not receiving adequate treatment. Additionally, 72.7% of cancer survivors participated in the NHSP, and the undertreatment rate for dyslipidemia was significantly lower in the screened group compared to the non-screened group (34.14% vs. 44.78%; P < 0.001). Adjusting for age and sex, cancer survivors in the non-screened group had a significantly higher risk of not receiving appropriate dyslipidemia treatment (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.10, 1.97). Even after considering socioeconomic and cancer-related factors, the non-screened group remained significantly associated with undertreatment of dyslipidemia (OR 1.36, 95% CI: 1.02, 1.82), especially among female cancer survivors (OR 1.49, 95% CI: 1.05, 2.14).
Conclusions
This study is the first to assess the association between NHSP and undertreatment of dyslipidemia. Encouraging cancer survivors to participate in the NHSP would be an effective strategy to reduce the incidence and mortality of concurrent cardiovascular disease, ultimately improving the overall health of cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract